Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Citi Upgrades Ionis Pharmaceuticals (IONS) to Neutral
May 4, 2023 6:27 AM EDTCiti analyst David Lebowitz upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Sell to Neutral with a price target of $36.00 (from $30.00).
The analyst comments "Upgrading to Neutral, Raising PT to $36 (+$6) Eplontersen prospects in ATTR is a key driver for LT growth. Recently reported full data continues to suggest eplontersen is... More
